跳至主要内容
临床试验/NCT01135602
NCT01135602Unknown4 期

Topiramate for Hospitalized Patients With Alcoholism: a 12-Week Open-Label Study

Chiang Mai University1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2010年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
入组人数
150
试验地点
1
主要终点
Cognition

研究概览

简要总结

12-week, open-label study of topiramate in hospitalized patients with alcoholism

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Patients hospitalized due to alcohol-related problems
  • DSM-IV-TR alcohol dependence
  • >/= 35 drinks/week (male) or >/= 28 drinks/week (female) for >/= 1 week during four weeks prior to the admission
  • AUDIT score >/= 8
  • Mild or no alcohol withdrawal
  • Body mass index > 18 kg/m2
  • No pregnancy and no plan for pregnancy (female)
  • Intention to decrease or stop drinking

排除标准

  • Severe psychiatric and cognitive disorders
  • Other substance dependence, except nicotine and caffeine dependence, during 6 months prior to enrollment
  • Taking antipsychotics, mood stabilizers, anticonvulsants, opioid analgesics, systematic steroids, carbonic anhydrase inhibitors, hydrochlorthiazide, metformin, pioglitazone, or disulfiram
  • Moderate to high risk of suicide
  • Medical history of narrow angle glaucoma, renal impairment, kidney stones, and seizures
  • Unstable medical conditions
  • Plan to receive a formal treatment for alcoholism from other treatment settings
  • Under legal process
  • Pregnancy and nursing woman
  • Abnormal laboratory tests, including blood urea nitrogen, creatinine, electrolytes, and fasting blood sugar

研究组 & 干预措施

Topiramate

Experimental

1 group

干预措施: Topiramate (Drug)

结局指标

主要结局

Cognition

时间窗: 12 weeks

Cognition will be assessed by the use of Montreal Cognitive Assessment (MoCA)

次要结局

  • Alcohol drink/day(12 weeks)

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验